Objective-To determine the efficacy of fibrinolytic therapy with tissue
Canclusions-Alteplase was an effective treatment of arterial thrombosis after cardiac catheterisation in infants and children. Further studies are needed to determine whether lower doses will reduce the frequently observed bleeding complications. (Br Heartj 1993; 70:382-385) Femoral artery thrombosis is a common complication of retrograde arterial cardiac catheterisation in infants and children. [1] [2] [3] [4] [5] Though severe tissue ischaemia causing amputation of the affected leg is rare, impairment of the growth and function of the leg can become severe, suggesting that treatment of femoral artery thrombosis is mandatory in this age group.6" Surgical thrombectomy has been performed with varying success in children. 8 1) . After 24 hours heparin was stopped and alteplase (Actilyse) was infused at a rate of 05 mg/kg/h for the first hour followed by 0-25 mg/kg/h until pulses were palpable and blood pressure in both legs was similar or bleeding complications occurred. Except for those cases with severe bleeding complications, the heparin infusion (300 U/kg/day) was continued to 24 hours after alteplase treatment was stopped.
LABORATORY TESTING Before treatment with alteplase was started a complete blood cell count was obtained and prothrombin time (PT) activated partial thromboplastin time (aPTT), thrombin time, fibrinogen, antithrombin III, liver enzymes (aspartate and alanine aminotransferases), urea, and creatinine were measured. Fibrinogen, thrombin time, PT, and aPTT were measured before, 2, 4, 8, and 24 h after starting treatment with alteplase.
Results
Clot dissolution (fig 2) was complete in 16 patients. In one patient poor skin perfusion and pallor disappeared, posterior tibial pulses became palpable, and blood pressure in both legs was similar after six hours of alteplase treatment but the tibial pulses disappeared again 15 hours after alteplase was stopped. At thrombectomy a 10 cm long clot was recovered from the femoral artery of this patient. In one patient pulses reappeared and alteplase was stopped four hours after treatment started despite reduced blood pressure in the catheterised leg (table). This did not accord with the study protocol. This patient was discharged with partial clot dissolution and reduced blood pressure in the affected leg. Nine months later his pulses were normal and there was no blood pressure difference between the legs.
The mean duration of lysis was 7-1 (range 4-11 h). Eight patients bled from the arterial puncture site. In three bleeding was severe and they had to be treated with packed erythrocytes because of acute hypotension or a decrease of haematocrit of >15% or both. In one of these three patients compression of the puncture site had been stopped too soon after the ultrasonographic examination. One patient showed mild epistaxis. No thrombosis after cardiac catheterisation. 14 Bleeding complications were seen in nine without, but bleeding was more common in patients (53%), with bleeding and oozing older patients. The mean age of patients with from the arterial entry site, and all were conbleeding was 26-9 months, whereas in trolled by groin compression. Bleeding always patients without bleeding it was 16-7 months. occurred when clinical signs of reperfusion of the leg appeared. Levy et al reported a similar LABORATORY DATA high rate of bleeding complications in chilFibrinogen concentrations remained constant dren when the dose of alteplase was 046-0-5 during the first two hours of treatment and mg/kg/h.16 fell by a mean of 045 g/l from the second to Low concentrations of fibrinogen at the the fourth hour of treatment. By 24 hours end of fibrinolytic treatment seemed to correafter starting alteplase, fibrinogen concentra-late with bleeding complications: mean fibtions had increased by a mean of 055 g/l (fig rinogen was lower in patients with bleeding  3) . PT, aPIT, and thrombin times showed than in patients without. In patients with no clear trend.
bleeding complications mean fibrinogen was Fibrinogen concentrations at the end of lower at the end of lysis than before the start fibrinolytic treatment were known in seven of alteplase treatment. In patients without patients without bleeding complications and bleeding complications the fibrinogen conin five patients with bleeding from the arterial centration remained constant. Close monitorpuncture site. The mean fibrinogen concen-ing of fibrinogen during alteplase treatment tration was 3X44 g/l in the group without may aid recognition of patients at an bleeding and 2-15 g/l in the group with bleed-increased risk of bleeding complications. ing. Fibrinogen concentrations at the end of Bleeding and a decrease in fibrinogen did not fibrinolytic treatment had increased by 018 seem to be correlated with duration of treatg/l in the group without bleeding complica-ment, but bleeding was more common in tions and decreased by Because bleeding complications were common, however, further studies with lower doses of alteplase in combination with heparin and doses adjusted for age will be required.
